<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="vaccines-08-00098-t002" orientation="portrait" position="float">
 <object-id pub-id-type="pii">vaccines-08-00098-t002_Table 2</object-id>
 <label>Table 2</label>
 <caption>
  <p>Summary of viral hemorrhagic fever (VHF) research in HIS mice.</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Agent</th>
    <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Mouse Model</th>
    <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Virus Strain</th>
    <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Route, Dose</th>
    <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Survival</th>
    <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Main Findings</th>
    <th align="left" valign="top" style="border-top:solid thin;border-bottom:solid thin" rowspan="1" colspan="1">Ref.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>
      <italic>Filoviridae</italic>
     </bold>
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
   </tr>
   <tr>
    <td rowspan="5" align="left" valign="top" style="border-bottom:solid thin" colspan="1">EBOV</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NSG-huPBL</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">MA-EBOV
     <break/>Mayinga
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IP, 10³ PFU
     <break/>IP, 10³ PFU
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">0%
     <break/>100%
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">MA-EBOV infections induced human lymphocyte apoptosis and human cytokine response, but wild-type EBOV (Mayinga) infection did not</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B36-vaccines-08-00098" ref-type="bibr">36</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu-NSG-A2</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Mayinga
     <break/>Mayinga
     <break/>Makona
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IP, 10³ FFU
     <break/>IN, 10³ FFU
     <break/>IN, 10³ FFU
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">13% (1/8)
     <break/>7% (1/14)
     <break/>57% (4/7)
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Disease severity may correlate with human cell engraftment efficiency</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>,
     <xref rid="B38-vaccines-08-00098" ref-type="bibr">38</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu‑NSG‑SGM3</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Makona</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IM, 10³ FFU</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">50% (3/6) 
     <sup>‡</sup>
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Higher EBOV replication in liver compared to RESTV investigated in parallel</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B39-vaccines-08-00098" ref-type="bibr">39</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">NSG-BLT</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Mayinga
     <break/>
     <break/>Makona
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IP, 10², 10³ and 10
     <sup>5</sup> TCID
     <sub>50</sub>
     <break/>IP, 10² TCID
     <sub>50</sub>
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">0% (0/13)
     <break/>25% (1/4)
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Donor-dependent variations in severity observed</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B40-vaccines-08-00098" ref-type="bibr">40</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">TKO-BLT</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Makona</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IM, 10
     <sup>3</sup> FFU
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">44% (4/9) *</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Accumulation of dysfunctional M2-like macrophages</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B41-vaccines-08-00098" ref-type="bibr">41</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">SUDV</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu-NSG-A2</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Gulu-808892</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, 10
     <sup>3</sup> FFU
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">29% (2/7)</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Lethality rate analogous to human case fatality rates</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">TAFV</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu-NSG-A2</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Pauleoula-CI</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, 10
     <sup>3</sup> FFU
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">82% (9/11)</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Lethal TAFV infection produced high serum AST but low viremia</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">BDBV</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu-NSG-A2</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Bundibugyo-200706291</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, 10
     <sup>3</sup> FFU
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">29% (2/7)</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Lethality rate similar to human case fatality rates</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>]
    </td>
   </tr>
   <tr>
    <td rowspan="2" align="left" valign="top" style="border-bottom:solid thin" colspan="1">RESTV</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu‑NSG‑SGM3</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">RESTV-Pennsylvania</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IM, 10
     <sup>3</sup> FFU
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">100% (6/6) 
     <sup>‡</sup>
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">No gross pathology, RESTV levels lower than EBOV levels in liver</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B39-vaccines-08-00098" ref-type="bibr">39</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu-NSG-A2</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">RESTV-Pennsylvania</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IN, 10
     <sup>3</sup> FFU
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">80% (12/15)</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Lethal RESTV infection correlated with inflammation and high RESTV replication in the liver</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B37-vaccines-08-00098" ref-type="bibr">37</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">MARV</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">TKO-BLT</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Angola-368</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IM, 10
     <sup>3</sup> FFU
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">25% (2/8) *</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">MARV replicated similarly to EBOV, but induced more functional innate immune response</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B41-vaccines-08-00098" ref-type="bibr">41</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>
      <italic>Nairoviridae</italic>
     </bold>
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">CCHFV</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu‑NSG‑SGM3</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Turkey-200406546
     <break/>Oman-199809166
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IP, 10
     <sup>4</sup> TCID
     <sub>50</sub>
     <break/>IP, 10
     <sup>4</sup> TCID
     <sub>50</sub>
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">0% (0/5)
     <break/>100% (6/6)
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Strain-dependent severity. Time to death 13–23 days. Animals with terminal outcomes showed higher levels of perforin positive CD8 T cells. CCHFV-Turkey associated hepatic and neurological histopathology</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B42-vaccines-08-00098" ref-type="bibr">42</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>
      <italic>Phenuiviridae</italic>
     </bold>
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">RVFV</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu‑NSG‑SGM3</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">rZH-501
     <break/>rZH-501
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IM, 10
     <sup>1</sup> TCID
     <sub>50</sub>
     <break/>IM, 10
     <sup>4</sup> TCID
     <sub>50</sub>
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">0% (0/7)
     <break/>0% (0/7)
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Human immune cells did not alter disease course; murine cytokines still influential in humanized mouse models</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B43-vaccines-08-00098" ref-type="bibr">43</xref>]
    </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">
     <bold>
      <italic>Hantaviridae</italic>
     </bold>
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1"> </td>
   </tr>
   <tr>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">HTNV</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">hu-NSG-A2
     <break/>hu-NSG
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Strain 76-118
     <break/>Strain 76-118
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">IP, 10
     <sup>5</sup> FFU
     <break/>IP, 10
     <sup>5</sup> FFU
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">25% (2/8) *
     <break/>25% (2/8) *
    </td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">Human immune cells increase pathology; human CD8 T cell responses accelerated early pathology; human platelet loss during infection</td>
    <td align="left" valign="top" style="border-bottom:solid thin" rowspan="1" colspan="1">[
     <xref rid="B44-vaccines-08-00098" ref-type="bibr">44</xref>]
    </td>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <fn>
   <p>
    <sup>‡</sup>, until 14 dpi; *, until 21 dpi; IM, intramuscular; IN, intranasal; IP, intraperitoneal; MA, mouse-adapted.
   </p>
  </fn>
 </table-wrap-foot>
</table-wrap>
